Biotech | April 25, 2022
Shilpa Medicare receives NoC for biosimilar Aflibercept
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Partnership with Modality, award-winning GP super partnership
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
New kit enhances menu of FFPE solutions and allows oncology researchers to extract higher yields of concentrated DNA compared to traditional techniques
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
This product will be manufactured at Lupin’s Nagpur facility in India
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
The peptide-based vaccine induces a t cell-dependent response
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
Subscribe To Our Newsletter & Stay Updated
